MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC

Gene

Volumn 587, Issue 2, 2016, Pages 147-154

  Ma, Jun ^a   Zhao, Zhenxian ^a   Wu, Kaiming ^a   Xu, Zhe ^a   Liu, Kuanzhi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

ABT 737; Chemoresistance; Cisplatin; MCL 1; NSCLC; Obatoclax

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; OBATOCLAX; PROTEIN BAK; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; BAK1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PYRROLE DERIVATIVE;

A549 CELL LINE; ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC50; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; UPREGULATION; CARCINOMA, NON-SMALL-CELL LUNG; COMBINATION DRUG THERAPY; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES;

EID: 84966659056     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.04.054     Document Type: Article

References (40)

1. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009, 66:1326-1336. (PMID: 19099185).
2. Albershardt T.C., Salerni B.L., Soderquist R.S., Bates D.J., Pletnev A.A., Kisselev A.F., Eastman A. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J. Biol. Chem. 2011, 286:24882-24895. (PMID: 21628457).
3. Bodur C., Basaga H. Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr. Med. Chem. 2012, 19:1804-1820. (PMID: 22414090).
4. Chiappori A., Williams C., Northfelt D.W., Adams J.W., Malik S., Edelman M.J., Rosen P., Van Echo D.A., Berger M.S., Haura E.B. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J. Thorac. Oncol. 2014, 9:121-125. (PMID: 24346101).
5. Choi Y.M., Kim H.K., Shim W., Anwar M.A., Kwon J.W., Kwon H.K., Kim H.J., Jeong H., Kim H.M., Hwang D., Kim H.S., Choi S. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS ONE 2015, 10. (PMID: 26247588).
6. Craig R. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454. (PMID: 11960321).
7. Ettinger D.S., Wood D.E., Hughes M., et al. Non-small cell lung cancer, version 6.2015. J. Natl. Compr. Cancer Netw. 2015, 13:515-524. (PMID: 25964637).
8. Gariboldi M.B., Taiana E., Bonzi M.C., Craparotta I., Giovannardi S., Mancini M., Monti E. The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil. Cancer Lett. 2015, 364:156-164. (PMID: 25979228).
9. Harnett C.C., Abusneina A., Clément J., Gauthier E.R. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis. Cell Biochem. Funct. 2015, 33:334-340. (PMID: 26178811).
10. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006, 355:1763-1771. (PMID: 17065637).
11. Hu J, Xu C, Cheng B, Jin L, Li J, Gong Y, Lin W, Pan Z, Pan C. Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy. Tumour Biol. 2015. (PMID: 26219890).
12. Jiang C., Long J., Liu B., Xie X., Kuang M. Mcl-1 is a novel target of miR-26b that is associated with the apoptosis induced by TRAIL in HCC cells. Biomed. Res. Int. 2015, 2015:572738. (PMID: 26078955).
13. Juergens R., Brahmer J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?. Curr. Oncol. Rep. 2007, 9:255-264. (PMID: 17588349).
14. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478:23-43. (PMID: 11406167).
15. Khaw S.L., Huang D.C., Roberts A.W. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011, 43:525-535. (PMID: 21881535).
16. Koehler B.C., Scherr A.L., Lorenz S., Urbanik T., Kautz N., et al. Beyond cell death-antiapoptotic bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS ONE 2013, 8. (PMID: 24098503).
17. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., Bornmann W., Kantarjian H., Viallet J., Samudio I., Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68:3413-3420. (PMID: 18451169).
18. Kremer K.N., Peterson K.L., Schneider P.A., Meng X.W., Dai H., Hess A.D., Smith B.D., Rodriguez-Ramirez C., Karp J.E., Kaufmann S.H., Hedin K.E. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J. Biol. Chem. 2013, 288:22899-22914. (PMID: 23798675).
19. Lee W.S., Park Y.L., Kim N., Oh H.H., Son D.J., Kim M.Y., Oak C.Y., Chung C.Y., Park H.C., Kim J.S., Myung D.S., Cho S.B., Joo Y.E. Myeloid cell leukemia-1 regulates the cell growth and predicts prognosis in gastric cancer. Int. J. Oncol. 2015, 46:2154-2162. (PMID: 25672320).
20. Lee H.S., Park J.B., Lee M.S., Cha E.Y., Kim J.Y., Sul J.Y. Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin. Mol. Med. Rep. 2015, 12:4782-4788. (PMID: 26100106).
21. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007, 26:3972-3979. (PMID: 17173063).
22. Naka A., Takeda R., Shintani M., Ogane N., Kameda Y., Aoyama T., Yoshikawa T., Kamoshida S. Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am. J. Cancer Res. 2015, 5:2285-2293. (PMID: 26328259).
23. Ou Y., Zhai D., Wu N., Li X. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Gene 2015, 572:116-122. (PMID: 26143754).
24. Palve V., Mallick S., Ghaisas G., Kannan S., Teni T. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS ONE 2014, 9. (PMID: 25409302).
25. Perciavalle R.M., Stewart D.P., Koss B., Lynch J., Milasta S., Bathina M., Temirov J., Cleland M.M., Pelletier S., Schuetz J.D., Youle R.J., Green D.R., Opferman J.T. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 2012, 14:575-583. (PMID: 22544066).
26. Prathapan A., Vineetha V.P., Raghu K.G. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One 2014, 9. (PMID: 24788441).
27. Schimmer A.D., Raza A., Carter T.H., Claxton D., Erba H., DeAngelo D.J., Tallman M.S., Goard C., Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS ONE 2014, 9. (PMID: 25285531).
28. Shi M., Yan S.G., Xie S.T., Wang H.N. Tip30-induced apoptosis requires translocation of Bax and involves mitochondrial release of cytochrome c and Smac/DIABLO in hepatocellular carcinoma cells. Biochim. Biophys. Acta 2008, 1783:263-274. (PMID: 17997990).
29. Shoshan-Barmatz V., Keinan N., Abu-Hamad S., Tyomkin D., Aram L. Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo. Biochim. Biophys. Acta 2010, 1797:1281-1291. (PMID: 20214874).
30. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30. (PMID: 23335087).
31. Subhash V.V., Tan S.H., Tan W.L., Yeo M.S., Xie C., Wong F.Y., Kiat Z.Y., Lim R., Yong W.P. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer 2015, 15:550. (PMID: 26209226).
32. Sui Y., Yang Y., Wang J., Li Y., Ma H., Cai H., Liu X., Zhang Y., Wang S., Li Z., Zhang X., Wang J., Liu R., Yan Y., Xue C., Shi X., Tan L., Ren J. Lysophosphatidic acid inhibits apoptosis induced by cisplatin in cervical cancer cells. Biomed. Res. Int. 2015, 2015:598386. (PMID: 26366416).
33. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399. (PMID: 17097561).
34. van Oosterwijk J.G., Herpers B., Meijer D., Briaire-de Bruijn I.H., Cleton-Jansen A.M., Gelderblom H., van de Water B., Bovée J.V. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann. Oncol. 2012, 23:1617-1626. (PMID: 22112972).
35. Vela L., Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr. Opin. Pharmacol. 2015, 23:74-81. (PMID: 26079328).
36. Wang C., Youle R.J. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 2012, 31:3177-3189. (PMID: 22056880).
37. Willis S.N., Chen L., Dewson G., Wei A., Naik E., et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305. (PMID: 15901672).
38. Yin W., Nie Y., Zhang Z., Xie L., He X. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Oncol. Rep. 2015, 34:368-374. (PMID: 25997995).
39. Zhang Y., Zhu X., Hou K., Zhao J., Han Z., Zhang X. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis. Oncol. Rep. 2015, 33:2277-2284. (PMID: 25812695).
40. Zheng Y., Lv X., Wang X., Wang B., Shao X., Huang Y., Shi L., Chen Z., Huang J., Huang P. miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol. Rep. 2016, 35:683-690. (PMID: 26572075).